Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.

Autor: Minig L; Gynecology Department, Instituto Valenciano de Oncología (IVO), C/del Profesor Beltrán Baguena 8, 46009, Valencia, Spain. miniglucas@gmail.com., Cabrera S; Gynecology Department, Hospital Universitario Vall d`Hebron, Barcelona, Spain., Oliver R; Gynecology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain., Couso A; Gynecology Department, Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain., Rubio MJ; Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain., Iacoponi S; Gynecology Department, Hospital Universitario Quirón, Madrid, Spain., Martin-Salamanca MB; Gynecology Department, Hospital Universitario de Getafe, Madrid, Spain., Carballo-Rastrilla S; Gynecology Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Canarias (CHUIMI), Gran Canaria, Islas Canarias, Spain., Cádenas-Rebollo JM; Department of Applied Mathematics and Statistics, CEU San Pablo University, Madrid, Spain., García-Garcia A; Gynecology Department, Instituto Valenciano de Oncología (IVO), C/del Profesor Beltrán Baguena 8, 46009, Valencia, Spain., Gil-Ibáñez B; Gynecology Department, Hospital Universitario Vall d`Hebron, Barcelona, Spain., Juan-Fita MJ; Medical Oncology Department, Instituto Valenciano de Oncología (IVO), Valencia, Spain., Patrono MG; Gynecology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2018 Oct; Vol. 20 (10), pp. 1337-1344. Date of Electronic Publication: 2018 Apr 05.
DOI: 10.1007/s12094-018-1865-9
Abstrakt: Objective: To determine the incidence of serous tubal intraepithelial carcinoma (STIC) after risk reduction salpingo-oophorectomy(RRSO), and to describe oncological outcomes after RRSO.
Materials and Methods: BRCA pathogenic mutation carriers who had undergone an RRSO were evaluated in this retrospective multicenter observational study. Patients were only included when fallopian tubes were analyzed following the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM). Surgeries were performed between June 2010 and April 2017 at eight Spanish hospitals.
Results: A total of 359 patients met the inclusion criteria. STIC was diagnosed in 3 (0.8%) patients; one of them underwent surgical staging due to positive peritoneal washing, with absence of disease at the final pathology report. None of the three patients received adjuvant chemotherapy and were free of disease at last follow-up. Fallopian tube and ovarian carcinoma were diagnosed in 5 (1.4%) and 1 (0.3%), respectively. At a median (range) follow-up time of 29 (3-92) months, five patients had a newly diagnosed breast cancer. Other types of cancer, which were diagnosed during the follow-up time, included: serous primary peritoneal carcinoma (n = 1), serous endometrial carcinoma (n = 1), colon (n = 1), pancreas (n = 1), jaw (n = 1), and lymphoma (n = 1). Seven patients died due to different types of cancer: breast (n = 4), pancreas (n = 1), jaw (n = 1), and colon (n = 1).
Conclusion: The incidence of STIC after RRSO in BRCA mutation carriers is low (0.8%) and it presents an excellent oncological outcome. Patients after RRSO, however, run the risk to develop other types of cancer during follow-up and should be properly advised before the prophylactic surgery.
Databáze: MEDLINE
Externí odkaz: